Stroke Prevention in Atrial Fibrillation


Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period December 12, 2011 through December 12, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the 6 segments totaling 2 hours and 15 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in stroke prevention in the setting of atrial fibrillation.

Release Date:

December 12, 2011

Expiration Date:

December 12, 2013

Intended Audience:

  • Cardiovascular specialists
  • Prevention-focused cardiologists
  • Thrombosis specialists
  • Anticoagulation specialists
  • Internal medicine specialists
  • Electrophysiology/Heart Rhythm specialists
  • Anticoagulation-focused clinical pharmacists
  • Cardiovascular nursing specialists
  • Neurologists


Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by an educational grant from
Janssen Pharmaceuticals, Inc.,
administered by Janssen Scientific Affairs, LLC

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosures:

Samuel Z. Goldhaber, MD – Program Chairman
Senior Staff Physician, Director, VTE Research Group
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical Sc

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis

Associate Physician Cardiovascular Division
Brigham and Women's Hospital
Instructor of Medicine
Harvard Medical School
Boston, MA

Grant/Research Support: Daiichi-Sankyo. Coinvestigator ENGAGEAF – TIMI 48 Trial. Research Grant to TIMI

Director, Clinical Cardiology Services
The Cardiovascular Institute, Mount Sinai Medical Center
Robert and Harriet Professor of Medicine (Cardiology)
Mount Sinai School of Medicine
New York, NY

Consultant: Astellas Pharma, U.S., Bayer Healthcare, Biotronik, Inc., Boehringer Ingelheim, Daiichi Sankyo Pharma, J&J, Sanofi-Aventis

Professor of Medicine
McMaster University
Consultant Physician
Department of Medicine, Hamilton Health Services
Hamilton, Ontario, Canada

Consultant: Bayer, Johnson & Johnson, Pfizer, Astellas
Speaker's Bureau: GlaxoSmithKline, Bayer Canada

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this acivity, attendees of this program will:

  • Better understand the evidence basis and clinical implications of the evolving, multidimensional landscape for anticoagulation-based management in chronic AF
  • Better understand and be able to deploy evidence-based, risk-specific interventions across the comprehensive (low, moderate, and high risk) spectrum of patient subgroups with AF
  • Be better able to risk stratify patients with atrial fibrillation (AF) in order to determine guideline-consistent and risk-specific treatment based on age, comorbid features, risks and benefits or anticoagulation therapy
  • Learn how to optimize residual stroke risk reduction in AF in low, moderate and high risk patient populations, and how to employ the CHADS2, CHADS-VASC, and HAS-BLED risk stratification tools to assist selection of therapies for AF
  • Learn how to systematically analyze late-breaking landmark SPAF trials — including ROCKET AF, ARISTOTLE, and RE-LY — focusing on thromboembolic risk prevention in patients with atrial fibrillation

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.




I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved



Key Program Topics Include:

ACC/AHA/ESC Guidelines
Atrial Fibrillation


Factor Xa Inhibitor
Intracerebral Hemorrhage
Myocardial infarction
Pulmonary embolism

RE-LY Trial
rhythm control
Valvular Atrial Fibrillation